7-二氟甲基-5-甲基-吡唑并-[1,5-a]嘧啶-3-羧酸 | 438218-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 7-二氟甲基-5-甲基-吡唑并-[1,5-a]嘧啶-3-羧酸
• 中文别名: 7-二氟甲基-5-甲基-吡唑[1,5-A]嘧啶-3-羧酸
• 英文名称: 7-(difluoromethyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid
• CAS: 438218-14-5
• 化学式: C₉H₇F₂N₃O₂
• mdl: MFCD02253706
• 分子量: 227.17
• InChiKey: YYIJNWNMCIXAJD-UHFFFAOYSA-N

物化性质

• 密度：
  1.62±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  67.5
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7-二氟甲基-5-甲基-吡唑并-[1,5-a]嘧啶-3-羧酸 、 4-乙基苯胺 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 7-(difluoromethyl)-N-(4-ethylphenyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide
  参考文献：
  名称：

  Discovery, Structure–Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase

  摘要：

  A major challenge in the field of Gaucher disease has been the development of new therapeutic strategies including molecular chaperones. All previously described chaperones of glucocerebrosidase are enzyme inhibitors, which complicates their clinical development because their chaperone activity must be balanced against the functional inhibition of the enzyme. Using a novel high throughput screening methodology, we identified a chemical series that does not inhibit the enzyme but can still facilitate its translocation to the lysosome as measured by immunostaining of glucocerebrosidase in patient fibroblasts. These compounds provide the basis for the development of a novel approach toward small molecule treatment for patients with Gaucher disease.

  DOI：

  10.1021/jm300063b
• 作为产物：
  描述：

  1,1-二氟乙酰基乙酮 在 水 、 溶剂黄146 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 7-二氟甲基-5-甲基-吡唑并-[1,5-a]嘧啶-3-羧酸
  参考文献：
  名称：

  Discovery, Structure–Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase

  摘要：

  A major challenge in the field of Gaucher disease has been the development of new therapeutic strategies including molecular chaperones. All previously described chaperones of glucocerebrosidase are enzyme inhibitors, which complicates their clinical development because their chaperone activity must be balanced against the functional inhibition of the enzyme. Using a novel high throughput screening methodology, we identified a chemical series that does not inhibit the enzyme but can still facilitate its translocation to the lysosome as measured by immunostaining of glucocerebrosidase in patient fibroblasts. These compounds provide the basis for the development of a novel approach toward small molecule treatment for patients with Gaucher disease.

  DOI：

  10.1021/jm300063b

文献信息

• [EN] AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES<br/>[FR] DÉRIVÉS DE CYCLOHEXANE À SUBSTITUTION AMIDO
  申请人：BAYER PHARMA AG

  公开号：WO2016177658A1

  公开（公告）日：2016-11-10

  The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.

  本发明涉及一般式(I)的酰胺取代环己烷化合物，其中A、R4、R6、R7、R8、R9、R10和R11如本文所定义，涉及制备所述化合物的方法，涉及用于制备所述化合物的中间化合物，涉及包含所述化合物的药物组合物和药物组合物，以及用于制造用于治疗或预防疾病的药物组合物的所述化合物的用途，特别是肿瘤，作为唯一药剂或与其他活性成分结合使用。
• Design of pyrazolo-pyrimidines as 11β-HSD1 inhibitors through optimisation of molecular electrostatic potential
  作者：Graeme R. Robb、Scott Boyd、Christopher D. Davies、Alexander G. Dossetter、Frederick W. Goldberg、Paul D. Kemmitt、James S. Scott、John G. Swales

  DOI：10.1039/c5md00043b

  日期：——

  Rapid and efficient lead optimisation through quantification of the molecular electrostatic potential using quantum mechanics.

  通过量子力学对分子电荷势进行定量化，实现快速高效的铅优化。
• AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3292107A1

  公开（公告）日：2018-03-14
• Discovery, Structure–Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase
  作者：Samarjit Patnaik、Wei Zheng、Jae H. Choi、Omid Motabar、Noel Southall、Wendy Westbroek、Wendy A. Lea、Arash Velayati、Ehud Goldin、Ellen Sidransky、William Leister、Juan J. Marugan

  DOI：10.1021/jm300063b

  日期：2012.6.28

  A major challenge in the field of Gaucher disease has been the development of new therapeutic strategies including molecular chaperones. All previously described chaperones of glucocerebrosidase are enzyme inhibitors, which complicates their clinical development because their chaperone activity must be balanced against the functional inhibition of the enzyme. Using a novel high throughput screening methodology, we identified a chemical series that does not inhibit the enzyme but can still facilitate its translocation to the lysosome as measured by immunostaining of glucocerebrosidase in patient fibroblasts. These compounds provide the basis for the development of a novel approach toward small molecule treatment for patients with Gaucher disease.